-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the announcement of the National Food and Drug Administration (NMPA), Novo Nordisk's application for the listing of insulin deglubber and liraglutide injection has been updated to "under approval", which means that the drug is expected to Recently approved in China
The world's first marketed combination of basal insulin and GLP-1RA
Screenshot source: NMPA official website
Type 2 diabetes is a chronic metabolic disease, which accounts for the vast majority of diabetic patients
Among the numerous hypoglycemic drugs, glucagon-like peptide-1 (GLP-1) analogs are newer drugs with better effects and fewer side effects
Among the numerous hypoglycemic drugs, glucagon-like peptide-1 (GLP-1) analogs are newer drugs with better effects and fewer side effects
Image source: 123RF
Since the half-life of natural GLP-1 is very short, with a life span of only a few minutes, many long-acting GLP-1 analogs have been developed, and liraglutide is one of them
Liraglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner, and reduces body weight and body fat by increasing satiety and reducing energy intake
Insulin degludec is a new generation of ultra-long-acting basal insulin analogue, which has the characteristics of stable, safe and effective blood sugar control
Public information shows that as early as 2014, insulin deglulam and liraglutide injection were approved for marketing in the European Union, becoming the world's first approved combination of basal insulin and GLP-1RA
According to Novo Nordisk’s previous press release, insulin deglubber and liraglutide are complementary targets for each other and act on the pathogenesis of type 2 diabetes.
Insulin deglulam and liraglutide are complementary targets for each other and act on the pathogenesis of type 2 diabetes.
It can effectively reduce glycosylated hemoglobin (HbA1c), and the risk of hypoglycemia is low weight gain is less, the daily insulin dose is less to achieve better blood glucose control, and more patients achieve HbA1c <7% without hypoglycemia and/or weight gain , Lower daily dose of insulin
In September 2020, Novo De Nuo submitted a new drug listing application for deglu insulin and liraglutide injection in China and was accepted
references:
references:[1] Inquiry on the progress of drug registration of China National Medical Products Administration.
[1] Inquiry on the progress of drug registration of China National Medical Products Administration.
[2].
[3] [New Product Express: Insulin Deglulam/Liraglutide Injection] IDegLira China data hits.
[4] [New Product Express: Insulin degludec/liraglutide injection] IDegLira China data strikes again.
Retrieved Jan 27.
2021.
from https://mp.
weixin.
qq.
com/s/scnvrOCe03BhGsJRQiEJiw
